Literature DB >> 9719644

Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.

P S Chowdhury1, G Vasmatzis, R Beers, B Lee, I Pastan.   

Abstract

The conversion of the anti-mesothelin monoclonal antibody K1 to a single-chain Fv (scFv) that is fused to a truncated form of Pseudomonas exotoxin A (PE) results in a fusion protein (immunotoxin) that is unstable and refolds very inefficiently. We have devised a method that identifies candidate residues in the framework region of K1 Fv that, when mutated, improved the yield and stability of the protein. The method works by initially aligning the framework sequences of K1 VH and VL with those of other scFvs that are stable and give a good yield as immunotoxins. Then we assigned a character to each residue that indicates its state of exposure based on the known crystal structures of Fabs. This identifies residues that are not compatible with their environment in the folded state of the protein. Next we calculated the frequencies of different amino acids for each position of the Fvs based on the available sequence database. This identifies residues that are not commonly present in the conserved positions. If these residues are compatible with their exposure profile they are left unaltered. Otherwise, they are identified as candidate residues for mutation. We identified two such residues in the VH (T82 and A85) and two in the VL (H36 and V60) of K1 that did not seem appropriate for their respective positions. By mutating these residues in K1 into those that occur most commonly in the sequence database or in stable scFvs, we significantly improved the stability and yield of the K1 scFv immunotoxins. By making single and combined mutations we assessed the relative contribution of mutations at these four sites towards the stability and yield of K1 scFv immunotoxins. The method we devised is probably general and can be used to improve other scFvs. Copyright 1998 Academic Press

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719644     DOI: 10.1006/jmbi.1998.1980

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

1.  Functional aspects of co-variant surface charges in an antibody fragment.

Authors:  Nicolas Hugo; Virginie Lafont; Mervyn Beukes; Danièle Altschuh
Journal:  Protein Sci       Date:  2002-11       Impact factor: 6.725

2.  Directed evolution methods for overcoming trade-offs between protein activity and stability.

Authors:  Samuel D Stimple; Matthew D Smith; Peter M Tessier
Journal:  AIChE J       Date:  2019-10-09       Impact factor: 3.993

Review 3.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

4.  Frontier of therapeutic antibody discovery: The challenges and how to face them.

Authors:  Zhi-Jian Lu; Su-Jun Deng; Da-Gang Huang; Yun He; Ming Lei; Li Zhou; Pei Jin
Journal:  World J Biol Chem       Date:  2012-12-26

Review 5.  Designing immunotoxins for cancer therapy.

Authors:  Christopher A Pennell; Heidi A Erickson
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

7.  Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity.

Authors:  Bruce A Kerwin; Chelsey Bennett; Yan Brodsky; Rutilio Clark; J Alaina Floyd; Alison Gillespie; Bryan T Mayer; Megan McClure; Christine Siska; Michael S Seaman; Kelly E Seaton; Jeremy Shaver; Georgia D Tomaras; Nicole L Yates; Randal R Ketchem
Journal:  J Pharm Sci       Date:  2019-07-23       Impact factor: 3.534

Review 8.  Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.

Authors:  Seyed Mehdi Havaei; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 9.  Antibody-Based Approaches to Target Pancreatic Tumours.

Authors:  Marie Sorbara; Pierre Cordelier; Nicolas Bery
Journal:  Antibodies (Basel)       Date:  2022-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.